Viking Therapeutics's total assets for Q4 2025 were $715.73M, a decrease of -3.20% from the previous quarter. DE:1VT total liabilities were $76.67M for the fiscal quarter, a 190.57% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.